Literature DB >> 17179940

Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening.

L Lucats1, B Ghaleh, P Colin, X Monnet, A Bizé, A Berdeaux.   

Abstract

BACKGROUND AND
PURPOSE: Postsystolic wall thickening (PSWT) is part of thickening that occurs after end-systole and represents wasted effort as it does not contribute to ejection. The effects of antianginal drugs on PSWT remain to be established. We compared the effects on PSWT of two agents that reduce heart rate, the beta-blocker atenolol and the selective inhibitor of If current, ivabradine. EXPERIMENTAL APPROACH: Six dogs were prepared to measure wall thickening by sonomicrometry in the conscious state, at rest and during exercise, after administration of saline, atenolol (1 mg.kg-1) or ivabradine (1 mg.kg-1). KEY
RESULTS: Atenolol and ivabradine similarly reduced heart rate vs saline at rest (about 10-20%) and during exercise (about 30%). Atenolol but not ivabradine decreased dP/dtmax. Concomitantly, PSWT increased with atenolol vs saline at rest (0.35+/-0.07 vs 0.21+/-0.03 mm, respectively) and during exercise (0.30+/-0.04 vs 0.15+/-0.04 mm, respectively). In contrast, ivabradine did not alter PSWT. Importantly, atenolol but not ivabradine increased the ratio of postsystolic to systolic wall thickening by 80+/-23%. This enhanced thickening during diastole with atenolol was accompanied by impeded isovolumic relaxation of the left ventricle, as illustrated by the significant correlation between the isovolumic relaxation time constant tau and the postsystolic to systolic wall thickening ratio. None of these effects of atenolol were abolished when heart rate was controlled with atrial pacing. CONCLUSION AND IMPLICATIONS: For a similar heart rate reduction at rest and during exercise, ivabradine, but not atenolol, did not alter PSWT and preserved the part of thickening contributing to ejection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17179940      PMCID: PMC2013893          DOI: 10.1038/sj.bjp.0706996

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise.

Authors:  Patrice Colin; Bijan Ghaleh; Luc Hittinger; Xavier Monnet; Michel Slama; Jean-François Giudicelli; Alain Berdeaux
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

2.  Abnormal postsystolic thickening in acutely ischemic myocardium during coronary angioplasty: a velocity, strain, and strain rate doppler myocardial imaging study.

Authors:  F Jamal; T Kukulski; J D'hooge; I De Scheerder; G Sutherland
Journal:  J Am Soc Echocardiogr       Date:  1999-11       Impact factor: 5.251

3.  Identification of acutely ischemic myocardium using ultrasonic strain measurements. A clinical study in patients undergoing coronary angioplasty.

Authors:  Tomasz Kukulski; Fadi Jamal; Lieven Herbots; Jan D'hooge; Bart Bijnens; Liv Hatle; Ivan De Scheerder; George R Sutherland
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

4.  Regional asynchrony during acute myocardial ischemia quantified by ultrasound strain rate imaging.

Authors:  C Pislaru; M Belohlavek; R Y Bae; T P Abraham; J F Greenleaf; J B Seward
Journal:  J Am Coll Cardiol       Date:  2001-03-15       Impact factor: 24.094

5.  Rapid ventricular pacing induces delayed cardioprotection against myocardial stunning.

Authors:  Laurence Lucats; Virginie Chalvignac; Alain Bizé; Xavier Monnet; Roland Zini; Luc Hittinger; Alain Berdeaux; Bijan Ghaleh
Journal:  J Mol Cell Cardiol       Date:  2005-10-19       Impact factor: 5.000

6.  Measurement of postsystolic shortening to assess viability and predict recovery of left ventricular function after acute myocardial infarction.

Authors:  H Hosokawa; F H Sheehan; T Suzuki
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

7.  Postsystolic shortening in ischemic myocardium: active contraction or passive recoil?

Authors:  Helge Skulstad; Thor Edvardsen; Stig Urheim; Stein Inge Rabben; Marie Stugaard; Erik Lyseggen; Halfdan Ihlen; Otto A Smiseth
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

8.  Incidence and characteristics of segmental postsystolic longitudinal shortening in normal, acutely ischemic, and scarred myocardium.

Authors:  Jens-Uwe Voigt; Gerd Lindenmeier; Bert Exner; Matthias Regenfus; Dierk Werner; Udo Reulbach; Uwe Nixdorff; Frank A Flachskampf; Werner G Daniel
Journal:  J Am Soc Echocardiogr       Date:  2003-05       Impact factor: 5.251

9.  Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs.

Authors:  Jean-Paul Vilaine; Jean-Pierre Bidouard; Ludovic Lesage; Hélène Reure; Jean-Louis Péglion
Journal:  J Cardiovasc Pharmacol       Date:  2003-11       Impact factor: 3.105

10.  Contributions of heart rate and contractility to myocardial oxygen balance during exercise.

Authors:  Patrice Colin; Bijan Ghaleh; Xavier Monnet; Jinbo Su; Luc Hittinger; Jean-Francois Giudicelli; Alain Berdeaux
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-10-24       Impact factor: 4.733

View more
  6 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

2.  Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression.

Authors:  Nicolas Couvreur; Renaud Tissier; Sandrine Pons; Valérie Chetboul; Vassiliky Gouni; Patrick Bruneval; Chantal Mandet; Jean-Louis Pouchelon; Alain Berdeaux; Bijan Ghaleh
Journal:  Eur Heart J       Date:  2009-12-21       Impact factor: 29.983

Review 3.  Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.

Authors:  Cosmo Godino; Antonio Colombo; Alberto Margonato
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 4.  Preclinical results with I(f) current inhibition by ivabradine.

Authors:  Alain Berdeaux
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.

Authors:  G Heusch
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 6.  Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.

Authors:  Pietro Scicchitano; Francesca Cortese; Gabriella Ricci; Santa Carbonara; Michele Moncelli; Massimo Iacoviello; Annagrazia Cecere; Michele Gesualdo; Annapaola Zito; Pasquale Caldarola; Domenico Scrutinio; Rocco Lagioia; Graziano Riccioni; Marco Matteo Ciccone
Journal:  Drug Des Devel Ther       Date:  2014-06-03       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.